News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Market Value To Reach $2.9 Billion By 2019, Says GBI Research

3/18/2014 9:08:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK (GBI Research), 18 March 2014 -- The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region — Australia, China, India and Japan — is expected to increase moderately over the coming years, climbing from $1.8 billion in 2012 to $2.9 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 6.3%, forecasts business intelligence provider GBI Research.

According to the company’s latest report*, Japan and China had the largest shares of the region’s NSCLC market in 2012, with 48.5% and 41.5%, respectively. Meanwhile, Australia and India had lower shares of 5.9% and 4.1%.

Sravanthi Addapally, Senior Analyst for GBI Research, says that an aging population and increasing number of NSCLC incident cases, especially in China and India, will be the main drivers behind the anticipated market growth.

“Additionally, the expected launches of premium-priced novel antibodies and immunotherapies in the first and second lines of therapies, targeting both Squamous and Non-Squamous NSCLC patients, will widen the eligible treatment population. This will ultimately maximize the patient share and provide a boost for the market,” Addapally says.

Currently, the NSCLC pipeline is very strong, with a total of 290 active molecules in development, either as monotherapies or in combination with chemotherapy. Promising candidates in the late-stage clinical trials include second-generation Tyrosine-Kinase Inhibitors, such as Pfizer’s dacomitinib and Boehringer Ingelheim’s Gilotrif. This latter therapy is currently a pre-registration drug in Japan for Epidermal Growth Factor Receptor-positive patients.

Addapally concludes: “In spite of many expected drug launches, growth in this treatment market is forecast to be marginal due to the dominant generic penetration of NSCLC drugs in India. A complex and lengthy regulatory pathway and limited reimbursement from national insurance programs in China, as well as regular price cuts in Japan, will also hinder further market expansion in the APAC region.”

*NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

This report analyzes the non-small cell lung cancer (NSCLC) treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in Australia, China, India and Japan.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus